Adam Brufsky, MD, PhD

Adam Brufsky, MD, PhD, FACP, discusses background and previous clinical data on palbociclib as a treatment option for patients with estrogen receptor-positive, HER2-negative, advanced breast cancer.

While results of the PALOMA-2 study did not show a survival benefit for the overall population on the combination of palbociclib and letrozole but did show an overall survival benefit in Black patients on the combination therapy.

Adam Brufsky, MD, PhD, FACP, discusses the real-world efficacy of letrozole in combination with palbociclib as treatment of patients with estrogen receptor-positive, HER2-negative, advanced breast cancer, based on race and ethnicity.